MAPT and Alzheimer disease: The use of biomarkers such as quantification of Aβ and tau levels in cerebrospinal fluid (CSF) or the increased deposition of tau tangles and accumulation of Aβ plaques revealed by positron emission tomography (PET) are biomarkers that help determine the clinical stage of AD; however, they are limited because they require invasive techniques and expensive diagnostic tools [6].